Phenylacetic acid β-phenylisopropylamide | 38084-50-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Phenylacetic acid β-phenylisopropylamide
• 英文别名: (+/-)-phenylacetic acid-(1-methyl-2-phenyl-ethylamide)；phenyl-acetic acid-(1-methyl-2-phenyl-ethylamide)；(+/-)-Phenylessigsaeure-(1-methyl-2-phenyl-aethylamid)；N-(1-Methyl-2-phenyl-aethyl)-C-phenyl-acetamid；Phenyl-essigsaeure-(1-methyl-2-phenyl-aethylamid)；Phenylessigsaeure-(1-methyl-2-phenyl-ethylamid)；2-Phenylacetamide, N-(1-phenyl-2-propyl)-；2-phenyl-N-(1-phenylpropan-2-yl)acetamide
• CAS: 38084-50-3
• 化学式: C₁₇H₁₉NO
• 分子量: 253.344
• InChiKey: XFZHLFPIVVALNE-UHFFFAOYSA-N

物化性质

• 熔点：
  113-115 °C
• 沸点：
  460.5±34.0 °C(Predicted)
• 密度：
  1.060±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  Phenylacetic acid β-phenylisopropylamide 在 lithium aluminium tetrahydride 作用下， 以 苯 为溶剂， 以55%的产率得到1-苯基-N-(2-苯基乙基)丙烷-2-胺
  参考文献：
  名称：

  来自 α-苯基异丙胺衍生物的药用化合物。八。一系列 α-苯基异丙胺衍生物的药理活性依赖于结构

  摘要：

  一些化合物的合成在前面已经描述过：II-VI[i]、VII-XI[2]、XII[3]、XIV和XV[4]。[5]中描述了化合物XIII的二盐酸盐。它是通过用铁在乙酸中还原 4,4'-二硝基二苯乙酸的 8-苯基异丙基酰胺而制备的。然而，作者没有分离出该基地，并指出它不稳定，在空气中迅速变暗。在目前的工作中，我们研究了在雷尼镍存在下作为还原剂的水合肼。该程序以非常好的收率得到4.4'-二氨基二苯乙酸的8-苯基异丙基酰胺。它是完全稳定的，长期储存不会发生变化。化合物XVI和XVII分别通过4-氨基苯乙酸II和苯乙酸的8-苯基异丙基酰胺的氢化铝锂还原得到。

  DOI：

  10.1007/bf00760702
• 作为产物：
  描述：

  非那明 、 苯乙酰氯 在 sodium hydroxide 作用下， 生成 Phenylacetic acid β-phenylisopropylamide
  参考文献：
  名称：

  Dey; Ramanathan, Proceedings of the National Institute of Sciences of India, 1943, vol. 9, p. 193,222

  摘要：

  DOI：

文献信息

• AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS
  申请人：CHEMAPOTHECA, LLC

  公开号：US20180243241A1

  公开（公告）日：2018-08-30

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  这项发明还涉及包含高纯度苯丙胺和苯丙胺类化合物的药物组合物，这些化合物是通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的，并且涉及通过对手性和消旋苯丙胺衍生物进行立体特异性、区域选择性的杯酸盐加成反应与环氧乙烷磷酰胺化合物合成而得到的苯丙胺化合物的制造、输送和使用方法。
• Methods of Treatment Using Amphetamine Controlled Release, Prodrug, and Abuse Deterrent Dosage Forms
  申请人：CHEMAPOTHECA, LLC

  公开号：US20210030699A1

  公开（公告）日：2021-02-04

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  本发明还涉及制备高纯度苯丙胺及苯丙胺类化合物的药物组合物，该组合物是通过使用手性和消旋苯丙胺衍生物合成，利用具有立体选择性和区域选择性的杯酸铜加成反应与环氧乙烷磷酰胺化合物反应所得到的。本发明还涉及制备、传递和使用通过使用手性和消旋苯丙胺衍生物合成，利用具有立体选择性和区域选择性的杯酸铜加成反应与环氧乙烷磷酰胺化合物反应所得到的苯丙胺类化合物的方法。
• Amphetamine controlled release, prodrug, and abuse-deterrent dosage forms
  申请人：CHEMAPOTHECA, LLC

  公开号：US11123310B2

  公开（公告）日：2021-09-21

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.

  本发明还涉及药物组合物，其中包含通过与氮丙啶磷酰胺化合物的立体特异性、区域选择性杯突加成反应合成手性和外消旋安非他明衍生物所得到的高纯度安非他明和安非他明类化合物，以及通过与氮丙啶磷酰胺化合物的立体特异性、区域选择性杯突加成反应合成手性和外消旋安非他明衍生物所得到的安非他明化合物的制造、交付和使用方法。
• N-Acyl-β-phenethylamines, and a New Isoquinoline Synthesis
  作者：John J. Ritter、Francis X. Murphy

  DOI：10.1021/ja01123a053

  日期：1952.2
• METHODS OF TREATMENT USING AMPHETAMINE CONTROLLED RELEASE, PRODRUG, AND ABUSE-DETERRENT DOSAGE FORMS
  申请人：CHEMAPOTHECA, LLC

  公开号：US20200352883A1

  公开（公告）日：2020-11-12

  The invention also relates to pharmaceutical compositions comprising highly pure amphetamine and amphetamine-class compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds, and to methods of manufacturing, delivering, and using the amphetamine compounds resulting from the synthesis of chiral and racemic amphetamine derivatives by stereospecific, regioselective cuprate addition reaction with aziridine phosphoramidate compounds.